Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Betta Pharmaceuticals Co., Ltd.)"
Count: 60
Selected: 0
NCT IDTitle
NCT03222622Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
NCT02801435Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
NCT05007938Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
NCT04946890A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT04930432Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04464551The Absorption, Metabolism and Excretion of [14C]D-0316 in Human
NCT04415320X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
NCT04206072D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
NCT04058704A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
NCT03804541The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
NCT03791112A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor
NCT03754530Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
NCT03749213Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
NCT03608007X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
NCT03536481Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers
NCT03510611A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
NCT03396185Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
NCT03349203Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
NCT03346811Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
NCT03215693X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
NCT03188848Dose Escalating Study of BPI-3016 in Healthy Subjects
NCT02959619Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
NCT02929290Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC
NCT02914990Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
NCT02726568High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
NCT02574091Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
NCT02544789Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
NCT02486354Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
NCT02478866Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
NCT02448797Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
NCT02404675High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
NCT02328261A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
NCT02278458Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
NCT02215356Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
NCT02194556Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
NCT02125240Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
NCT02103257Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
NCT02066870Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
NCT02062515Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
NCT02044328Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
NCT02027090High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
NCT02024633Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
NCT01929200Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
NCT01926171Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
NCT01855854Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
NCT01843647Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
NCT01720901Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
NCT01719536Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
NCT01707329Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
NCT01690390Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease